S. Vassiliadis, GROWTH OF HUMAN AML CELL-LINES ON BONE-MARROW FEEDER LAYERS IS SUPPORTED BY CELLULAR INTERACTIONS RATHER THAN GROWTH-FACTOR PRODUCTION, Haematologia, 26(1), 1994, pp. 29-37
Leukemia is characterized by an excessive and anomalous cell growth wh
ich does not permit the cells to mature normally. Many cellular oncoge
nes have been shown to regulate such behavior and the participation of
various growth factors has been implicated in the same process. The e
tiology of the proliferative stimulus is examined here and it is found
that the cause of accelerated growth is mainly due to cellular intera
ctions via surface contact. In order to reproduce the in vivo situatio
n, that is the genesis and maturation of cells in the bone marrow comp
artment, acute myelogenous leukemia (AML) cells in the form of cell li
nes as well as primary APML cells were seeded on top of normal bone ma
rrow feeder layers used as the supporting cellular surface. First, it
is shown that direct contact between the two different populations res
ults in increased proliferation of the seeded population as feeders, i
nactivated by irradiation, still stimulate cellular and do not promote
differentiation. Second, it is demonstrated that there is no granuloc
yte-monocyte colony-stimulating factor (GM-CSF), CSF-1, interleukin-3
(IL-3) and possibly stem cell factor (SCF) production by the marrow ce
lls during the contact. Third, when cell-to-cell contact is hindered b
y mechanically separating the cellular surfaces, allowing, however, th
e free transport of possibly produced growth factors (GF), the prolife
rative mte is reduced. Thus, the results demonstrate that cell contact
and not growth factor production is responsible for the increased gro
wth rate of these cells. However, this kind of proliferation can be re
versed by masking certain antigenic determinants of the feeder populat
ion by specific monoclonal antibodies directed against class I, II and
endothelial epitopes. This finding may be of importance for the contr
ol of the disease in future trials.